CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 23rd Annual Global Investment Conference as well as participate in one-on-one meetings with investors. The Conference will be held virtually with all participants joining remotely from September 13th - 15th.
H.C. Wainwright 23rd Annual Global Investment Conference
An on-demand corporate presentation will be accessible to conference attendees starting on Monday, September 13th 2021 at 7am ET for 90 days after the event. A link to the live audio webcast as well as the replay of the webcast can be found below and will be available on Reviva’s website, under the “Investors- News & Events” section at https://ir.revivapharma.com/.
Webcast Link: https://journey.ct.events/view/e5a91398-5796-4cb0-b911-bcde078067ef
For more information about the 23rd Annual Global Investment Conference, please visit the H.C. Wainwright conference website https://hcwevents.com/annualconference/. If you are interested in arranging a virtual one-on-one meeting, please contact your H.C. Wainwright representative or contact Bruce Mackle at LifeSciAdvisors.
Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential, “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
Investor Relations Contact:
LifeSci Advisors, LLC
Source: Reviva Pharmaceuticals
2021 GlobeNewswire, Inc., source Press Releases